Clinical Trial Results:
A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection
Summary
|
|
EudraCT number |
2010-021628-84 |
Trial protocol |
BE DE GB SE AT IE PL ES IT |
Global completion date |
28 Nov 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
14 Jul 2016
|
First version publication date |
14 Jul 2016
|
Other versions |
|
Summary report(s) |
VX-950-C211 (2010-021628-84)_(Telaprevir)_CT.gov Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.